AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06785623 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gastrodia elata Blume water extract
Description: Subjects in the experimental group will consume Gastrodia elata Blume water extract daily. The extract is prepared from dried Gastrodia elata Blume, which is processed into a water-soluble form. This dosage is administered orally for a duration of a week. The intervention is designed to evaluate the potential effects of Gastrodia elata Blume on alleviating depressive symptoms, improving autonomic nervous system function, and enhancing overall quality of life in terminal cancer patients.
Study NCT06785623 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Gastrodia elata Blume water extract
Description: Subjects in the experimental group will consume Gastrodia elata Blume water extract daily. The extract is prepared from dried Gastrodia elata Blume, which is processed into a water-soluble form. This dosage is administered orally for a duration of a week. The intervention is designed to evaluate the potential effects of Gastrodia elata Blume on alleviating depressive symptoms, improving autonomic nervous system function, and enhancing overall quality of life in terminal cancer patients.
Study NCT06786481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational with milnacipran
Description: Before starting the foot massage, the client is informed about the number, duration and time of the session. The average interview time with the patients in the experimental group will be 15-20 minutes. The first interview with the women in the experimental group will be held at any time after the birth when the woman feels well. Before the application, the researcher washes and dries her hands and warms them appropriately by massaging with baby oil and facilitates the process. First, a three-minute general massage is performed to prepare the feet, and then the correct points for each foot are massaged for 10 minutes. 'Introductory Information Form', LATCH Breastfeeding Diagnostic Measurement Tool, Newborn Stress Scale and Pittsburgh Sleep Quality Index (PSQI) forms will be filled. The woman's address and telephone details will be taken to meet again.
Study NCT06786481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Locally Directed Therapy
Description: Before starting the foot massage, the client is informed about the number, duration and time of the session. The average interview time with the patients in the experimental group will be 15-20 minutes. The first interview with the women in the experimental group will be held at any time after the birth when the woman feels well. Before the application, the researcher washes and dries her hands and warms them appropriately by massaging with baby oil and facilitates the process. First, a three-minute general massage is performed to prepare the feet, and then the correct points for each foot are massaged for 10 minutes. 'Introductory Information Form', LATCH Breastfeeding Diagnostic Measurement Tool, Newborn Stress Scale and Pittsburgh Sleep Quality Index (PSQI) forms will be filled. The woman's address and telephone details will be taken to meet again.
Study NCT06786312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 250mg, P.O, qd, 21 days per cycle;
Study NCT06786312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: 20mg/kg or 1200mg ivgtt, d1, 21 days per cycle;
Study NCT06786312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Injection
Description: 100mg/m\^2 ivgtt for the first, second and third consecutive days, 21 days per cycle.
Study NCT06786312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin Injection
Description: Day 1 administration, AUC=5, intravenous infusion; One treatment cycle every 21 days.
Study NCT06783712 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal block
Description: Group I: Patients will receive the ultrasound-guided Adductor canal block (ACB) by the supervisors of the research performed just after skin closure. ACB will be performed under complete aseptic conditions. Using a high frequency (6-15MHz) linear probe of an ultrasound machine (Sonosite turbo M, Bothell, Washington, USA) covered with a sterile sheath and 100 mm needle SonoPlex (B-Braun Medical Inc., Bethlehem, PA, USA). ACB block will be performed while the patient is in a supine position at the point midway between the anterior superior iliac spine and the upper pole of the patella. The adductor canal will be located as a hyperechoic structure beneath the sartorius muscle, 100 mm needle SonoPlex will be advanced with the guidance of ultrasound in an in-plane technique and 20 ml bupivacaine (Marcaine) 0.25% will be injected.
Study NCT06783712 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor Canal Block (ACB) + iPACK Block
Description: Group II: The patients will receive ACB by the supervisors of the research just after skin closure as previously described in group I and then an IPACK block will be performed. IPACK block will be performed under complete aseptic precautions using the ultrasound machine with the high-frequency linear probe covered with a sterile sheath and 100 mm needle SonoPlex. IPACK block will be performed while the patient is in a supine position with slight knee flexion, the probe will be applied to the popliteal fossa for identification of the popliteal artery and femur. Then the probe will be distally slided for revealing the two femoral condyles followed by proximal sliding of the probe until the humps of the femoral condyles disappear and the flat metaphysis appear. A needle will be advanced from the lateral aspect and directed across the space between the popliteal artery and femur and once the needle reaches the medial edge of the femur,20 ml bupivacaine 0.25% will be injected incrementally
Study NCT06787846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Group TP
Description: Serum : Application full face, twice daily, in the morning and at bedtime for 4 months and application Tinted sunscreen SPF 50+, twice a day
Study NCT06787846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Group HQ: Hydroquinone 4%
Description: Cream : Application all over the face once a day (at bedtime) and Tinted sunscreen SPF 50+, twice a day
Study NCT06782880 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Description: To assess if heterologous FMT is more effective than autologous FMT in reducing the rate of major infection episodes within 6-months after OLT.
Study NCT06782880 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Fecal microbiota transplantation (FMT)
Description: To assess if heterologous FMT is more effective than autologous FMT in reducing the rate of major infection episodes within 6-months after OLT.
Study NCT06785727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin (atorvastatin, fluvastatin, pravastatin, rosuvastatin or simvastatin)
Description: The intervention group receives statin treatment following the current Herseninfarct en Hersenbloeding guideline. The intensity and target value of statin treatment are determined according to this national guideline. Which statin (atorvastatin, fluvastatin, pravastatin, rosuvastatin, simvastatin) will be selected and what dose will be prescribed is left to the discretion of the treating neurologist. The statins are registered in the Netherlands and use will be according to the licenses of the products. They will be collected at the local pharmacy by the patient (following practice as usual).
Study NCT06784830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effects on Image Quality and Patient Satisfaction
Description: Effect of nursing intervention on image quality and patient satisfaction during PET/CT imaging in Alzheimer's patients
Study NCT06784830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anxiety degree of patients after nursing
Description: Self Rating Anxiety will be used Scale (SAS) to assess the degree of anxiety after care
Study NCT05886036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy
Study NCT05886036 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo tissue biopsy
Study NCT05886036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05886036 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05886036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT05886036 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT05886036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT05886036 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT05886036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Receive FDG
Study NCT05886036 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fludeoxyglucose F-18
Description: Receive FDG
Study NCT05886036 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Given SC
Study NCT05886036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT05886036 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT05194683 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relational Letter Writing
Description: The intervention consists of two interviews and a between-session writing task. In the first session, couples will be interviewed regarding their relationship story and preferences. Between the two sessions, each couple member will write a letter from their relationship point of view. In the second interview, the task is reviewed and paths for relationship improvement are outlined.
Study NCT05331105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL-085
Description: IIa: HL-085 capsule 9mg administered orally twice daily in a continuous 21-day treatment cycle. If required, dosing schedule can be adjusted to 12mg BID, 6mg BID, or other dosage regimens.~IIb: HL-085 at the recommended dose or dosage regimen.
Study NCT05886036 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Given IV
Study NCT05886036 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab and Hyaluronidase Human
Description: Given SC
Study NCT06785649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender herbal tea
Description: The participant will be allocated 14 pieces of lavender tea bags consisting of 2 grams and originating from Turkey. During 14 days, the participant will be advised to use 2 g of lavender herb brewed in 300 mL hot water for 10-15 minutes in the morning and evening. Participants will be able to use 1 lavender tea bag twice a day.
Study NCT04473534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web based cognitive-behavioral therapy
Description: one web session of psycho-education about sleep
Study NCT06786299 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RD-IIT-001
Description: Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy
Study NCT06786299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD84-CART
Description: Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy
Study NCT06785142 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Functional Shot
Description: 60ml functional energy shot contained a proprietary blend of L-theanine, chamomile, lemon balm, ginseng and vitamins
Study NCT06785142 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo Shot
Description: Placebo 60 ml Shot, matched in volume, taste and colour and but did not contain any active ingredients
Study NCT06783075 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MILK
Description: Drink containing amino acids in the composition of milk protein
Study NCT06783075 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WHEAT
Description: Drink containing amino acids in the composition of wheat protein
Study NCT06783400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SASA! Together
Description: SASA! Together is a community mobilisation approach that engages communities to create positive and sustainable changes around norms and behaviors that perpetuate violence against women. Some new features in this revision of SASA! include a distinct focus on IPV, including sexual decision-making; three strategies aligned to the socio-ecological model that reach across the whole community (individuals, groups, and institutions); and more support to get organisations and communities started and to sustain change.~The evidence- and theory-based SASA! approach is grounded in: (1) benefits-based activism, (2) a gender-power analysis, (3) four phases of change (start, awareness, support, action) according to the stages of behaviour change, (4) holistic community engagement, (5) local activism, (6) community leadership, and (7) institutional strengthening.
Study NCT06782659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP-001
Description: Oral liquid suspension of sildenafil
Study NCT06782659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viagra
Description: Sildenafil film-coated tablet
Study NCT06782659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASP-001
Description: Bottle/pump containing ASP-001 suspension
Study NCT06552403 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A modified 5:2 intermittent fasting diet
Description: The modified 5:2 IF diet involves 2 nonconsecutive fasting days (25%-30% of the total required daily energy intake based on ideal body weight) and 5 days of habitual intake (limited total energy intake according to ideal body weight) per week, as well as a 4-week run-in period and a minimum of 6,000 steps of physical activity per day.
Study NCT06787859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Showing a nature view curtain to type 2 diabetic patients during insulin injection
Description: a nature view curtain
Study NCT05305456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tanreqing capsule
Description: 3 capsules per time, 3 times a day
Study NCT05305456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tanreqing capsule simulator
Description: 3 capsules per time, 3 times a day
Study NCT05294809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PsyPills
Description: Prescribing personalized rational thinking strategies to change levels of dysfunctional emotionality.
Study NCT05294809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online-Contingent Attention Training, OCAT
Description: Facilitating the disengagement from negative content and engagement of positive one of personally relevant information by providing instruction and feedback on performance.
Study NCT05294809 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: shamOCAT
Description: The active control group, which consists of the fake version of the OCAT intervention, by offering the same attentional training, without training and feedback on performance.
Study NCT06784115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reminder App
Description: The purpose of the app is to remind patients irradiated for prostate cancer in an intuitive, unobtrusive and supportive way to drink 300 ml of water 45 minutes prior to each radiation session.
Study NCT06786351 — intervention group
Intervention type: PROCEDURE
Intervention: Right atrial balloon occlusion
Description: Thoracic endovascular aortic repair with right atrial balloon occlusion for reduction or elimination of aortic impulse and stent graft deployment in landing zones 0-3
Study NCT06786351 — intervention group
Intervention type: PROCEDURE
Intervention: Non right atrial balloon occlusion
Description: Thoracic endovascular aortic repair not using right atrial balloon occlusion for reduction or elimination of aortic impulse and stent graft deployment in landing zones 0-3
Study NCT06785051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI-based physiotherapy
Description: jaw, neck, shoulder ROM exercises, and scapular-focused exercises guided by AI technology, 30 minutes of intervention, once a week, and a total of 12 weeks
Study NCT06785051 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: jaw, neck, shoulder ROM exercises, and scapular-focused exercises, 30 minutes of intervention, once a week, and a total of 12 weeks
Study NCT06785051 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Scar management
Description: scar massage and jaw-mobilizing exercises combined with devices or depressors
Study NCT06785051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scar management
Description: scar massage and jaw-mobilizing exercises combined with devices or depressors
Study NCT06782555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evofosfamide
Description: Evofosfamide administered on Days 1 and 8 of Cycles 1, 2, and 3.
Study NCT06782555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zalifrelimab
Description: Zalifrelimab administered on Day 8 of Cycles 1, 3, and 5.
Study NCT06782555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Balstilimab administered every 2 weeks beginning on Day 8 of Cycle 1.
Study NCT06783855 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suspension uretheroileal technique
Description: The suspension technique is reported as the puboprostatic ligaments that attach the prostate to the symphysis pubis. After the ligating the complex, including both the dorsal vein complex and the puboprostatic ligaments, this complex was sharply divided anteriorly from the prostate with a safe distance (1-2 mm), and the urethra is defined and divided. After removing the prostate, the ileal pouch is reconstructed by completely everting the mucosa and sutured outward with a running 4-0 absorbable suture around the edge. The neck of the neobladder was narrowed to ≈1 cm, for convenient passage of a 20 F catheter. Anastomotic sutures of 3-0 absorbable polyglactin were placed at the 1, 3, 5, 6, 7, 9, 11 and 12 o'clock positions through the full thickness of the urethra
Study NCT06783855 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional radical cystectomy and ileal neobladder
Description: After removing the prostate, the ileal pouch is reconstructed by completely everting the mucosa and sutured outward with a running 4-0 absorbable suture around the edge. The neck of the neobladder was narrowed to ≈1 cm, for convenient passage of a 20 F catheter. Anastomotic sutures of 3-0 absorbable polyglactin were placed at the 1, 3, 5, 6, 7, 9, 11 and 12 o'clock positions through the full thickness of the urethra, including the mucosa and muscularis of the neobladder neck, ensuring mucosa-to-mucosa anastomosis
Study NCT06786650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenoxicam Injectable Product
Description: Analgesic efficacy of the two active agents analysed in our study in acute migraine attack has not been compared before.
Study NCT06786650 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: ibuprofen
Description: Analgesic efficacy of the two active agents analysed in our study in acute migraine attack has not been compared before.
Study NCT06787014 — intervention group
Intervention type: OTHER
Intervention: Histopathological review
Description: Histopathological review
Study NCT06786169 — intervention group
Intervention type: OTHER
Intervention: psychological stress status
Description: The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a PHQ-9 score ≥ 5 or a GAD-7 score ≥ 5 were categorized as the stressed group.
Study NCT06784869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scaling and root surface debritment
Description: Patients with 4-6 mm pocket depth were participated in this study; clinical periodontal parameters (BOP, PLI, PPD, CAL) were recorded at the baseline visit. To ensure sampling accuracy, From the site two papers with GCF were sampled. Following sample collecting for GCF, Every patient received comprehensive mouth supragingival scaling with an ultrasonic scaler (WoodpEEKer® UDS-K) along with dental hygiene recommendations. One week later, the sites were irrigated with normal saline after being scaled and root planed (ScRp) with Gracey curette. Following completion of subgingival instrumentation, each patient returned to the clinic following 1 and 3 months for periodontal parameter recording and GCF collection. Throughout these sessions, every patient received reinstruction to engage in self-oral hygiene practices.
Study NCT04878354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tree SLIT-tablet
Description: Sublingual allergy immunotherapy tablets
Study NCT04878354 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SLIT-tablet
Description: Placebo
Study NCT06272487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilebesiran
Description: Zilebesiran administered by subcutaneous (SC) injection
Study NCT06272487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered by SC injection